SpotX Infographic Reveals Growth of Connected TV Advertising in Europe
SpotX, the leading video advertising and monetisation platform for media owners, today unveils an infographic forecasting the growth of the connected TV advertising opportunity in Europe. The visual representation of research commissioned by SpotX, shows the growth of advertising on connected TV, defined as content served to the TV screen via the open internet through devices including smart TVs, game consoles, streaming media services such as the Amazon Fire Stick, Chromecast and Apple TV and pay TV subscriptions. Rapid growth is predicted with an increase of over 200% from €225m in 2016 to €825m in 2020.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180227006633/en/
SpotX infographic reveals growth of connected TV advertising in Europe (Graphic: SpotX)
The infographic is based on research conducted by MTM, a research and strategy consultancy, and commissioned by SpotX to discover the size of the connected TV advertising opportunity in Europe. The advancement of AVOD (advertising-funded Video-on-Demand) technology and the desire from brands and agencies to advertise alongside premium programmes has increased steadily, and the research shows that the market is now set for rapid growth across the big five TV advertising markets in Europe.
The infographic shows the UK is Europe’s largest market for connected TV advertising, expected to be worth €250m in 2020. The UK market will have a 19 percent compound annual growth rate (CAGR) which will be achieved through increased user engagement with connected TV technology combined with broadcasters’ commitment to providing market leading services such as the ITV Hub and BBC iPlayer.
Rapid connected TV advertising growth is pictured in Italy with participants in the research predicting an 80 percent CAGR between 2016 and 2020. The infographic shows the market is forecast to be €105m in two years time, growing from €10m in 2016. Developments in audience measurement signal the Italian industry is preparing for adoption as consumer interest in video on demand increases.
Alongside a strong culture of IPTV, the infographic illustrates that France will have the second highest connected TV advertising revenue with industry experts anticipating €240m to be generated by advertising delivered via the open internet to the TV screen in 2020. Market drivers such as good broadband penetration and speed are in place to sustain this growth and broadcasters will increase their investments into connected TV apps and services.
The infographic charts the growth of connected TV advertising in Germany from €50m in 2016 to €125 in 2020 with a CAGR of 24 percent, forecasting Germany to be the third largest market in two years time. The market enablers displayed in the infographic show that the investment is being made in the German market but that user adoption is slightly behind other countries in Europe with 50 percent of the population owning a smart TV.
Connected TV advertising is shown as €45m in 2016 in Spain with growth expected to reach €105m in 2020 which will equal revenues generated in Italy. Spain will see a predicted CAGR of 24 percent driven by demand from advertisers and agencies for connected TV inventory and by increased penetration of smart TVs in the market.
Mike Shehan, co-founder and CEO at SpotX explains, “The data shows the dramatic rise of adoption of connected TV advertising across Europe, reflecting the growth we have experienced already in the US. The story in the infographic has been reflected by our own expansion at SpotX working with leading European innovators such as STV, TV Player, Zattoo, The Box and Dugout on their strategies for global connected TV advertising revenue. The UK, France, and Germany are leading the adoption of connected TV advertising in Europe, followed by emerging markets with high potential including Spain and Italy.”
Nick Thomas, Associate Director at MTM adds, “This infographic illustrates the research we conducted showing how connected TV advertising is set for rapid growth in the next few years. Broadcasters are embracing the cross-device mindset of their digital-first audiences and advertisers clearly recognise the impact of their advertising appearing on the TV screen to targeted audiences.”
The infographic is based on research titled ‘The Connected TV Advertising Opportunity in Europe’ commissioned by SpotX, from MTM. The full report can be downloaded here.
SpotX is the leading video advertising platform providing publishers with monetisation tools for desktop, mobile and connected devices. The platform features modern ad serving and programmatic infrastructure, and other monetisation tools, like solutions for OTT and outstream video ad units. SpotX gives publishers the control, transparency and actionable insights needed to understand buyer behavior, manage access and pricing, and maximise revenue. The company is headquartered in Denver, Colorado, and has offices in Amsterdam, Belfast, Hamburg, London, Los Angeles, New York, Paris, San Francisco, Stockholm, Singapore, Sydney, and Tokyo. In October 2017, RTL Group, a leader across broadcast, content and digital, completed its 100% acquisition of SpotX and SpotX is now in the process of combining its business with smartclip. The combined entity will focus on ad-server development and addressable TV, which provide the Group with dynamic ad-insertion capabilities.For updates, follow SpotX on Twitter and LinkedIn.
VP, European Strategy
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27 | Pressemelding
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi